JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     



First published online March 17, 2010, 10.2967/jnumed.109.071449
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jnumed.109.071449v1
51/4/618    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in JNM
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Google Scholar
Right arrow Articles by Liu, B.
Right arrow Articles by Tian, R.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Liu, B.
Right arrow Articles by Tian, R.
Journal of Nuclear Medicine Vol. 51 No. 4 618-623
© 2010 by Society of Nuclear Medicine
doi: 10.2967/jnumed.109.071449

Basic Science Investigation

Influence of Vitamin C on Salivary Absorbed Dose of 131I in Thyroid Cancer Patients: A Prospective, Randomized, Single-Blind, Controlled Trial

Bin Liu, Anren Kuang, Rui Huang, Zhen Zhao, Yu Zeng, Jiantao Wang and Rong Tian

Department of Nuclear Medicine, West China Hospital, Sichuan University, Chengdu, China

Correspondence: For correspondence or reprints contact: Anren Kuang, Department of Nuclear Medicine, West China Hospital, Sichuan University, Guo Xuexiang 37, Chengdu 610041, China. E-mail: kuanganren{at}263.net

In this study, vitamin C was administered at various times as a sour stimulant to thyroid cancer patients, and the effect on salivary absorbed dose of therapeutic radioiodine (131I) was investigated. Methods: Patients with differentiated thyroid cancer who had been prepared for thyroid remnant ablation after total thyroidectomy were prospectively recruited and, using a random-number table, were divided into 4 groups. In the hypothyroid condition, the patients in groups A, B, C, and D began sucking vitamin C (100 mg every 4 h in the daytime over 6 d) at 1, 5, 13, and 25 h, respectively, after receiving 3.7 GBq of 131I. Scintigraphic images of the head and neck were serially acquired after 131I administration to assess biokinetics in the salivary glands. Calculation of salivary absorbed dose was based on the MIRD schema of the Society of Nuclear Medicine. Results: Seventy-two patients (18, 18, 19, and 17 patients from groups A, B, C, and D, respectively) were eligible for the analysis of salivary dosimetry. Differences in absorbed doses to the parotid salivary gland (0.18 ± 0.11, 0.16 ± 0.07, 0.16 ± 0.09, and 0.16 ± 0.12 mGy/MBq in groups A, B, C, and D, respectively; P = 0.37) and submandibular salivary gland (0.19 ± 0.05, 0.17 ± 0.05, 0.18 ± 0.07, and 0.17 ± 0.06 mGy/MBq, respectively; P = 0.28) were not statistically significant among groups. Salivary cumulated activities arising from the first 24 h after 131I administration accounted for 86.08% ± 7.89% (range, 75%–98%) of total cumulated activities. Differences in salivary absorbed dose during the first 24 h were not statistically significant among the 4 groups either (P = 0.32 and 0.24, respectively, for the parotid and submandibular salivary glands). Conclusion: Salivary stimulation with vitamin C at any time after 131I administration has only a limited effect on salivary absorbed dose in thyroid cancer patients.

Key Words: thyroid cancer • 131I • vitamin C • salivary gland • dosimetry

COPYRIGHT © 2010 by the Society of Nuclear Medicine, Inc.


Related articles in JNM:

This Month in JNM

JNM 2010 51: 11A-12A. [Full Text]  





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 2010 by the Society of Nuclear Medicine.